defer us trials until cashflow, page-7

jm69 - they could reduce quarterly expenditure by $1 mill by reducing R & D and related expenditue over the next 2-3 quarters, defer US trials until 2014. Possibly do another small raise with a sophisticated shareholder (maybe pp?).
If they were to do a largish CR in the next few months, it would be showing complete and utter contempt for LT holders IMHO....which unfortunately means they probably will do it on their record to date....